Contributions of PET and MRI imaging in the evaluation of CNS drugs in human neurodegenerative diseases

This manuscript reviews the contributions of the neuroimaging methods including PET, conventional and advanced MRI methods to monitor the effect of new disease modifying drugs in neurodegenerative diseases. It now seems obvious that in many pathologies these two techniques are more and more complementary. (c) 2020 Published by Elsevier Masson SAS on behalf of Societe francaise de pharmacologie et de therapeutique.

Automated summary

This manuscript reviews the contributions of neuroimaging methods such as PET and MRI, both conventional and advanced, in monitoring the effects of new disease modifying drugs in neurodegenerative diseases. The review highlights the increasing complementary nature of these techniques in various pathologies.